AstraZeneca AZN stock has risen 8.6% in the past month, mainly due to mixed fourth-quarter results and a positive update from ...

AstraZeneca PLC ADR closed 14.96% below its 52-week high of $87.68, which the company achieved on August 30th.

AstraZeneca (AZN) is set to acquire U.S. biotech company FibroGen’s (FGEN) China unit for $160 million to expand its presence in the country.

Allworth Financial LP boosted its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 12.9% in the fourth quarter, ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter.

In a phase 2 study, the company's medication suzetrigine barely performed better than a placebo in treating painful ...

In a report released today, Florent Cespedes from Bernstein maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target ...

AstraZeneca PLC outperforms 2024 earnings estimates but faces challenges in 2025. Read why AZN patent expiries and mixed ...

Judging from its top line, AstraZeneca had a stellar 2024, generating an 18% increase in revenue, with 14 of the products in ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

AstraZeneca's improving financial position isn't yet fully reflected in its stock price AstraZeneca's revenue was about $13.57 billion in the third quarter of 2024, up 18.1% year-over-year and 4. ...